GALT - Galectin Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development15,32513,1148,425
Selling General and Administrative6,1566,9657,005
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-21,481-20,079-15,430
Income from Continuing Operations
Total Other Income/Expenses Net455242
Earnings Before Interest and Taxes-21,436-20,027-15,388
Interest Expense---
Income Before Tax-21,436-20,027-15,388
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-21,436-20,027-15,788
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-21,436-20,027-15,788
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-22,350-21,124-16,960